ViroGates A/S

ViroGates A/S is located in Birkerød, Denmark on Banevænget 13. ViroGates A/S is rated 3 out of 5 in the category biotechnology in Denmark. ViroGates has developed a unique prognostic biomarker - suPARnostic®, measuring the soluble blood protein suPAR, present in everybody. The suPAR level is associated with presence, severity and progression of disease, and in unselected patients, suPAR is one of the strongest prognostic biomarkers available to date. suPARnostic® can improve the way seemingly low risk patients are managed - a low suPAR level helps avoid time and resources spent on further investigations, an elevated suPAR level is an indication that the patient is at higher risk of not surviving and it should be further investigated if this is caused by one or more developing diseases. The concept of adding the prognostic information of patient risk status gained from measuring suPAR to clinical decision making is starting to be applied in medical practices, allowing the doctor to prioritize patients and identify those who can be discharged from Acute Care because their prognosis is good. suPARnostic® increases patient safety, shortens the average patient-length-of-stay, reduces crowding and leads to significant cost savings for the hospital. ViroGates first commercial suPARnostic® product was an ELISA-based test, followed by a lateral flow Quick Triage test. ViroGates has launched the first suPARnostic® Turbilatex Test based on the turbidimetric technology, allowing doctors to obtain the suPAR result at the same time as other blood parameters are reported. The prognostic value of suPAR is validated by more than 500 clinical trials and publications in PubMed.